A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: arbitrate (1), intervene (25), reconcile (7)

Talimogene laherparepvec (T-VEC)

Description
Chemotherapy Protocol SKIN CANCER Talimogene laherparepvec (T-VEC) Regimen • Skin – Talimogene laherparepvec (T-VEC) Indication • Talimogene laherparepvec (T-VEC) is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Talimogene-laherparepvec-T-VEC.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Avelumab(800mg)

Description
Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indica
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Avelumab-Axitinib

Description
Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable loc
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description
Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description
Details of the Chemotherapy Protocol for Myeloma.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf
11 to 20 of 23
Previous 1 2 3 Next